[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337205-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337205-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","secondary-cancer-after-androgen-deprivation-therapy-in-prostate-cancer-a-nationwide-study","Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer - A Nationwide Study","","Nationwide cohort research evaluates whether androgen deprivation therapy (ADT) use after newly diagnosed prostate cancer is linked to secondary cancers beyond prostate cancer. A total of 278,434 men were identified from January 1, 2002 to December 31, 2017, with 170,416 enrolled after exclusions and matched through individual matching followed by propensity score matching. Cox proportional hazards models estimated adjusted hazard ratios and 95% confidence intervals for all male cancers. Results show higher overall secondary cancer incidence with ADT, with increased brain and central nervous system malignancy incidence but reduced risks for several other cancer sites.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/secondary-cancer-after-androgen-deprivation-therapy-in-prostate-cancer-a-nationwide-study/337205/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/secondary-cancer-after-androgen-deprivation-therapy-in-prostate-cancer-a-nationwide-study/337205.png","ImageObject",300,407,{"name":42,"@type":43},"Theodora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study purpose regarding ADT and secondary cancers?","Question",{"text":63,"@type":64},"To determine whether ADT use after prostate cancer is associated with secondary cancers other than prostate cancer in a nationwide population-based cohort.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were participants selected and groups created?",{"text":68,"@type":64},"Men with newly diagnosed prostate cancer between 2002 and 2017 were identified, exclusions were applied, and ADT and non-ADT groups were formed using individual matching followed by propensity score matching.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main findings about secondary cancer risk after ADT?",{"text":72,"@type":64},"After propensity score matching, the ADT group had a higher overall secondary cancer incidence risk, with increased brain and other central nervous system cancer incidence, while risks were lower for several other cancer sites compared with the non-ADT group.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337205,1790122712,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","Original Article  \nProstate cancer  \npISSN: 2287-4208 / eISSN: 2287-4690  \nWorld J Mens Health 2025 Jan 43(1): 123-133  \n[https://doi.org/10.5534/wjmh.230237](https://doi.org/10.5534/wjmh.230237)  \nSecondary Cancer after Androgen Deprivation  \nTherapy in Prostate Cancer: A Nationwide Study  \nJae Heon Kim1, Gi Hwan Bae2, Jaehun Jung2,3, Tae Il Noh4  \n1Department of Urology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, 2Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, 3Department of Preventive Medicine, Gachon University College of Medicine, Incheon, 4Department of Urology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea  \nPurpose: Androgen signaling is associated with various secondary cancer, which could be promising for potential treatment using androgen deprivation therapy (ADT) . This study investigated whether ADT use was associated with secondary cancers other than prostate cancer in a nationwide population-based cohort.  \nMaterials and Methods: A total, 278,434 men with newly diagnosed prostate cancer between January 1, 2002 and December 31, 2017 were identified. After applying the exclusion criteria, 170,416 men were enrolled. The study cohort was divided into ADT and non-ADT groups by individual matching followed by propensity score matching (PSM) . Study outcomes were incidence of all male cancers. Cox proportional hazard regression models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of events.  \nResults: During a median follow-up of 4.5 years, a total of 11,059 deaths (6,329 in the ADT group and 4,730 in the nonADT group) after PSM were found. After PSM, the overall all-cause of secondary cancer incidence risk of the ADT group was higher than that of the non-ADT group (HR: 1.312, 95% CI: 1.23–1.36; adjusted HR: 1.344, 95% CI: 1.29–1.40) . The ADT group showed higher risk of overall brain and other central nervous system (CNS) cancer-specific incidence than the nonADT group (adjusted HR: 1.648, 95% CI: 1.21–2.24) . The ADT group showed lower risks of overall cancer-specific incidence for stomach, colon/rectum, liver/inflammatory bowel disease (IBD), gall bladder/extrahepatic bile duct, lung, bladder, and kidney cancers than the non-ADT group. When the duration of ADT was more than 2 years of ADT, the ADT group showed higher risk of cancer-specific incidence for brain and other CNS cancers but lower risk of cancer-specific incidence for liver/ IBD and lung cancers than the non-ADT group.  \nConclusions: This study demonstrates that ADT could affect cancer-specific incidence for various cancers.  \nKeywords: Cohort studies; Prostatic neoplasms; Receptors, androgen; Survival analysis  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([http://creativecommons.org/licenses/by-nc/4.0)](http://creativecommons.org/licenses/by-nc/4.0))[ ](http://creativecommons.org/licenses/by-nc/4.0))[which permits unrestricted non-commercial use](which permits unrestricted non-commercial use), distribution, and reproduction in any medium, provided the original work is properly cited.  \nReceived: Aug 21, 2023 Revised: Oct 15, 2023 Accepted: Dec 5, 2023 Published online Mar 14, 2024  \nCorrespondence to: Tae Il Noh  [https://orcid.org/0000-0002-5278-7672](https://orcid.org/0000-0002-5278-7672)  \nDepartment of Urology, Korea University College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Korea.  \nTel: +82-2-920-5530, Fax: +82-2-928-7864, E-mail: [allybaba04@gmail.com](allybaba04@gmail.com)  \nCorrespondence to: Jaehun Jung  [https://orcid.org/0000-0002-4856-3668](https://orcid.org/0000-0002-4856-3668)  \nDepartment of Preventive Medicine, Gachon University College of Medicine, 38-13 Dokjeom-ro 3beon-gil, Namdong-gu, Incheon 21565 , Korea. Tel: +82-32-458-2611, Fax: +82-32-458-2608, ","cbCaicwIgjQui02g","https://ap.wps.com/l/cbCaicwIgjQui02g","pdf",500353,11,"English","# Introduction\n## Androgen signaling and androgen receptor roles\n## Androgens/AR in cancer epidemiology and pathways\n# Materials and Methods\n## Study population and matching strategy\n## Outcomes and statistical analysis\n# Results\n## Mortality after propensity score matching\n## Secondary cancer incidence by ADT exposure\n## Effects by ADT duration","[{\"question\":\"What was the study purpose regarding ADT and secondary cancers?\",\"answer\":\"To determine whether ADT use after prostate cancer is associated with secondary cancers other than prostate cancer in a nationwide population-based cohort.\"},{\"question\":\"How were participants selected and groups created?\",\"answer\":\"Men with newly diagnosed prostate cancer between 2002 and 2017 were identified, exclusions were applied, and ADT and non-ADT groups were formed using individual matching followed by propensity score matching.\"},{\"question\":\"What were the main findings about secondary cancer risk after ADT?\",\"answer\":\"After propensity score matching, the ADT group had a higher overall secondary cancer incidence risk, with increased brain and other central nervous system cancer incidence, while risks were lower for several other cancer sites compared with the non-ADT group.\"}]","Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer - A Nationwide Study | PDF",1790018135,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15b3713ee6fabe238c192bfe9a77c499.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64dfa2b89178aad47203c1fdce408956.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be54026162f1aeff6b425c0fb5959d2a.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1833decc12fdf2706aa6783c7ce4b825.webp",980,1306]